HORNBILL: A First-in-Human Phase I/IIa Study of the Safety, Tolerability, and Early Pharmacodynamics of BI 764524 for Diabetic Macular Ischemia

Objective: To report safety and early pharmacodynamic results from a first-in-human trial of intravitreal (IVT) anti-semaphorin 3A antibody in participants with diabetic macular ischemia (DMI). Design: HORNBILL, a phase I/IIa study of BI 764524, comprised a nonrandomized, open-label, uncontrolled, s...

Descrición completa

Detalles Bibliográficos

Principais autores:	Quan Dong Nguyen, MD, MSc, Chirag Jhaveri, MD, Maged Habib, MD, Yasir J. Sepah, MBBS, Khaled Nassar, MD, PhD, Bartlomiej Krawczyk, PhD, Gudrun Simons, PhD, Andrea Giani, MD, Elizabeth Pearce, PhD, Martin Gliem, MD, Mohamed Ahmed, MBBCh, MD, Sobha Sivaprasad, DM
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2025-09-01
Series:	Ophthalmology Science
Assuntos:	Diabetic retinopathy Sema3A First-in-human Retinal nonperfusion Ischemia
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S266691452500079X
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!